^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    APL-103

    i
    Other names: APL-103, ES-072
    Company:
    Apollomics, Zhejiang Bossan Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    4years
    [VIRTUAL] First-in-Human Phase I Study of ES-072, an oral mutant-selective EGFR T790M inhibitor, in Non-Small Cell Lung Cancer (CTS-China 2020)
    No abstract available
    P1 data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR T790M
    |
    APL-103
    over4years
    First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. (PubMed, Clin Lung Cancer)
    ES-072 was safe and well tolerated in NSCLC patients harboring EGFR T790M mutations, and adverse events were controllable and reversible. A RP2D of 300 mg once daily was determined, and preliminary investigations showed promising antitumor activity.
    P1 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR mutation + EGFR T790M
    |
    APL-103